|
1
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart CJ, Doherty DA, Havlat M, Koay MH,
Leung YC, Naran A, O'Brien D, Ruba S, Salfinger S and Tan J:
Transtubal spread of endometrial carcinoma: Correlation of
intra-luminal tumour cells with tumour grade, peritoneal fluid
cytology, and extra-uterine metastasis. Pathology. 45:382–387.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maritschnegg E, Wang Y, Pecha N, Horvat R,
Van Nieuwenhuysen E, Vergote I, Heitz F, Sehouli J, Kinde I, Diaz
LA Jr, et al: Lavage of the uterine cavity for molecular detection
of Müllerian duct carcinomas: A Proof-of-Concept Study. J Clin
Oncol. 33:4293–4300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Panici Benedetti P, Basile S, Salerno MG,
Di Donato V, Marchetti C, Perniola G, Palagiano A, Perutelli A,
Maneschi F, Lissoni AA, et al: Secondary analyses from a randomized
clinical trial: age as the key prognostic factor in endometrial
carcinoma. Am J Obstet Gynecol. 210:363.e1–363.e10. 2014.
View Article : Google Scholar
|
|
6
|
Abu-Rustum NR1, Iasonos A, Zhou Q, Oke E,
Soslow RA, Alektiar KM, Chi DS and Barakat RR: Is there a
therapeutic impact to regional lymphadenectomy in the surgical
treatment of endometrial carcinoma? Am J Obstet Gynecol. 198(457):
e1–e6. 2008.
|
|
7
|
Lee HJ and Ormandy CJ: Elf5, hormones and
cell fate. Trends Endocrinol Metab. 23:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee HJ, Gallego-Ortega D, Ledger A,
Schramek D, Joshi P, Szwarc MM, Cho C, Lydon JP, Khokha R,
Penninger JM, et al: Progesterone drives mammary secretory
differentiation via RankL-mediated induction of Elf5 in luminal
progenitor cells. Development. 140:1397–1401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalyuga M, Gallego-Ortega D, Lee HJ, Roden
DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F,
Launchbury R, et al: ELF5 suppresses estrogen sensitivity and
underpins the acquisition of antiestrogen resistance in luminal
breast cancer. PLoS Biol. 10:e10014612012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pearton DJ, Smith CS, Redgate E, van
Leeuwen J, Donnison M and Pfeffer PL: Elf5 counteracts precocious
trophoblast differentiation by maintaining Sox2 and 3 and
inhibiting Hand1 expression. Dev Biol. 392:344–357. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chakrabarti R, Wei Y, Romano RA, DeCoste
C, Kang Y and Sinha S: Elf5 regulates mammary gland stem/progenitor
cell fate by influencing notch signaling. Stem Cells. 30:1496–1508.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan H, Qiu L, Xie X, Yang H, Liu Y, Lin X
and Huang H: ELF5 in epithelial ovarian carcinoma tissues and
biological behavior in ovarian carcinoma cells. Oncol Rep.
37:1412–1418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Endo A, Tomizawa D, Aoki Y, Morio T,
Mizutani S and Takagi M: EWSR1/ELF5 induces acute myeloid leukemia
by inhibiting p53/p21 pathway. Cancer Sci. 107:1745–1754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan H, Qiu L, Xie X, Yang H, Liu Y, Lin X
and Huang H: ELF5 in epithelial ovarian carcinoma tissues and
biological behavior in ovarian carcinoma cells. Oncol Rep.
37:1412–1418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grassmeyer J, Mukherjee M, deRiso J,
Hettinger C, Bailey M, Sinha S, Visvader JE, Zhao H, Fogarty E and
Surendran K: Elf5 is a principal cell lineage specific
transcription factor in the kidney that contributes to Aqp2 and
Avpr2 gene expression. Dev Biol. 424:77–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Risinger JI, Maxwell GL, Chandramouli GV,
Jazaeri A, Aprelikova O, Patterson T, Berchuck A and Barrett JC:
Microarray analysis reveals distinct gene expression profiles among
different histologic types of endometrial cancer. Cancer Res.
63:6–11. 2003.PubMed/NCBI
|
|
17
|
Chakrabarti R, Hwang J, Blanco Andres M,
Wei Y, Lukačišin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T,
et al: Elf5 inhibits the epithelial-mesenchymal transition in
mammary gland development and breast cancer metastasis by
transcriptionally repressing Snail2. Nat Cell Biol. 14:1212–1222.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q,
Zhao YM, Shi YH, Gao Q, Wu WZ, Qiu SJ, et al: HNRNPAB induces
epithelial-mesenchymal transition and promotes metastasis of
hepatocellular carcinoma by transcriptionally activating SNAIL.
Cancer Res. 74:2750–2762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oakes SR, Naylor MJ, Asselin-Labat ML,
Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard
MA, Chodosh LA, Pfeffer PL, et al: The Ets transcription factor
Elf5 specifies mammary alveolar cell fate. Genes Dev. 22:581–586.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kreizman-Shefer H, Pricop J, Goldman S,
Elmalah I and Shalev E: Distribution of estrogen and progesterone
receptors isoforms in endometrial cancer. Diagn Pathol. 9:772014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boks DE, Trujillo AP, Voogd AC, Morreau H,
Kenter GG and Vasen HF: Survival analysis of endometrial carcinoma
associated with hereditary nonpolyposis colorectal cancer. Int J
Cancer. 102:198–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong P, Kaneuchi M, Konno Y, Watari H,
Sudo S and Sakuragi N: Emerging therapeutic biomarkers in
endometrial cancer. BioMed Res Int. 2013:1303622013. View Article : Google Scholar : PubMed/NCBI
|
